

# PHARMACOPEIAL FORUM

**32**

**NUMBER 1**

**BIMONTHLY JANUARY–FEBRUARY 2006**

## **Featured in This Issue**

**USP has identified the following content areas in the January-February 2006 issue of *Pharmacopeial Forum* as noteworthy for the pharmaceutical industry worldwide:**

- Policies and Announcements
  - Postponement Clarification for General Chapters <1> and <905>
  - USP Issues Notice of Retraction for Residual Solvents
  - Expert Committee Summaries available on the USP Website
  - New PF comment schedule
- First Interim Revision Announcement
  - USP Monograph
    - Lithium Carbonate Extended-Release Tablets
  - Dietary Supplement Monographs
    - Goldenseal
    - Powdered Goldenseal
    - Powdered Goldenseal Extract
- Proposed New Monographs
  - 15 new USP monographs
  - 1 new NF monograph
  - 3 new Dietary Supplements monographs
- Proposed Revisions to General Test Chapters
  - <11> USP Reference Standards
  - <231> Heavy Metals
- Proposed Revisions to General Information Chapters
  - <2040> Disintegration and Dissolution of Dietary Supplements

**A detailed listing of the Table of Contents of the January–February issue of *Pharmacopeial Forum* follows.**



**U.S. PHARMACOPEIA**  
*The Standard of Quality<sup>SM</sup>*

---

---

# Table of Contents\*

PHARMACOPEIAL FORUM VOL. 32 NO. 1

JAN.–FEB. 2006

---

---

<b>STANDARDS DEVELOPMENT</b> .....	5
<b>HOW TO USE PF</b> .....	9
Section Descriptions .....	10
Committee Designations .....	12
Staff Directory .....	14
<b>POLICIES AND ANNOUNCEMENTS</b> .....	17
General Chapters ⟨1⟩ and ⟨905⟩ Postponements—Clarification .....	18
USP Issues Notice of Retraction for Residual Solvents .....	18
Revisions to Goldenseal Monographs .....	18
USP Director of Executive Secretariat Named .....	18
Expert Committee Summaries available on the USP Website .....	18
USP Announces the Chairs of the Information Expert Committees .....	18
USP Seeks Submission of Proposals for Stability Indicating Assay Procedures for Steroids .....	19
Call for High Priority Monographs for Drug Substances and Products, and Excipients .....	20
Pharmacopeial Education Courses .....	28
Visit the USP Web Site at ⟨ <a href="http://www.usp.org">http://www.usp.org</a> ⟩ .....	28
International Correspondence .....	28
How to Submit Comments .....	28
New Pharmacopeial Forum Public Review and Comment Period Deadlines .....	29
Publication and Comment Schedule .....	29
Publication Schedules .....	30
<b>FIRST INTERIM REVISION ANNOUNCEMENT</b> .....	33
<b>MONOGRAPHS (USP)</b> .....	35
Lithium Carbonate Extended-Release Tablets .....	35
<b>DIETARY SUPPLEMENTS-MONOGRAPHS</b> .....	35
Goldenseal .....	35
Powdered Goldenseal .....	36
Powdered Goldenseal Extract .....	36
ERRATA LIST FOR <i>USP29–NF24</i> .....	37
<b>IN-PROCESS REVISION</b> .....	39
<b>MONOGRAPHS (USP)</b> .....	43
Acetazolamide Oral Solution [ <i>new</i> ] (USP 30) .....	43
Acetazolamide Oral Suspension [ <i>new</i> ] (USP 30) .....	44
Albendazole Oral Suspension (USP 30) .....	46
Alprazolam Oral Suspension [ <i>new</i> ] (USP 30) .....	46
Amoxicillin Capsules (Proposal for 3 <sup>rd</sup> IRA) .....	47
Azathioprine Oral Suspension [ <i>new</i> ] (USP 30) .....	48
Baclofen Oral Solution [ <i>new</i> ] (USP 30) .....	49
Baclofen Oral Suspension [ <i>new</i> ] (USP 30) .....	51
Benazepril Hydrochloride Tablets [ <i>new</i> ] (USP 30) .....	52
Benzonatate Capsules (USP 30) .....	55
Bethanechol Chloride Oral Solution [ <i>new</i> ] (USP 30) .....	55
Bethanechol Chloride Oral Suspension [ <i>new</i> ] (USP 30) .....	57
Bromocriptine Mesylate Capsules (USP 30) .....	58
Calcitriol [ <i>new</i> ] (USP 30) .....	58
Calcitriol Injection [ <i>new</i> ] (USP 30) .....	61
Calcium Pantothenate (USP 30) .....	62
Captopril Oral Solution [ <i>new</i> ] (USP 30) .....	63

---

---

\* The *USP–NF* (*USP30–NF25*), the *Supplement* (*Supp*), or the *Interim Revision Announcement* (*IRA*) for which the revision proposal is targeted is shown in parentheses next to each proposed item.

Captopril Oral Suspension [ <i>new</i> ] (USP 30)	64
Carbamazepine (USP 30)	65
Cefonicid for Injection (USP 30)	67
Ceftazidime (USP 30)	67
Ceftazidime Injection (USP 30)	68
Ceftazidime for Injection (USP 30)	68
Chlorthalidone (USP 30)	68
Cilostazol [ <i>new</i> ] (USP 30)	69
Cimetidine Tablets (USP 30)	72
Clonazepam Oral Suspension [ <i>new</i> ] (USP 30)	73
Clopidogrel Bisulfate (USP 30)	74
Clopidogrel Tablets (USP 30) (Proposal for 3 <sup>rd</sup> IRA)	76
Clotrimazole Lozenges (USP 30)	78
Diltiazem Hydrochloride Oral Solution [ <i>new</i> ] (USP 30)	79
Diltiazem Hydrochloride Oral Suspension [ <i>new</i> ] (USP 30)	80
Dipyridamole Oral Suspension [ <i>new</i> ] (USP 30)	81
Dolasetron Mesylate Oral Solution [ <i>new</i> ] (USP 30)	83
Dolasetron Mesylate Oral Suspension [ <i>new</i> ] (USP 30)	84
Dronabinol (USP 30)	86
Felodipine Extended-Release Tablets (Proposal for 3 <sup>rd</sup> IRA)	89
Flucytosine Oral Suspension [ <i>new</i> ] (USP 30)	92
Flumazenil (USP 30)	94
Fluticasone Propionate (USP 30)	95
Fluticasone Propionate Nasal Spray [ <i>new</i> ] (USP 30)	97
Fluvastatin Sodium (USP 30)	103
Fluvastatin Capsules (USP 30)	105
Formoterol Fumarate [ <i>new</i> ] (USP 30)	106
Fosinopril Sodium [ <i>new</i> ] (USP 30)	110
Ganciclovir Oral Suspension [ <i>new</i> ] (USP 30)	113
Gemcitabine Hydrochloride (USP 30)	114
Hydroxyzine Hydrochloride (USP 30)	114
Iodoform (USP 30)	115
Irbesartan (USP 30)	115
Labetalol Hydrochloride Oral Solution [ <i>new</i> ] (USP 30)	116
Labetalol Hydrochloride Oral Suspension [ <i>new</i> ] (USP 30)	117
Lovastatin (USP 30)	118
Mebendazole Oral Suspension (USP 30)	119
Metolazone Oral Suspension [ <i>new</i> ] (USP 30)	119
Metoprolol Tartrate Oral Solution [ <i>new</i> ] (USP 30)	121
Metoprolol Tartrate Oral Suspension [ <i>new</i> ] (USP 30)	122
Miconazole Nitrate Cream (USP 30)	123
Morphine Sulfate Extended-Release Capsules (USP 30)	124
Naproxen Delayed-Release Tablets (USP 30)	124
Narasin Granular (USP 30)	124
Narasin Premix (USP 30)	126
Ondansetron Hydrochloride (USP 30)	126
Ondansetron Hydrochloride Oral Suspension [ <i>new</i> ] (USP 30)	127
Ondansetron Oral Solution (USP 30)	128
Oxaprozin (USP 30)	130
Oxaprozin Tablets (USP 30)	130
Pancuronium Bromide [ <i>new</i> ] (USP 30)	130
Paricalcitol (USP 30)	132
Piroxicam Cream [ <i>new</i> ] (USP 30)	134
Pseudoephedrine Sulfate (USP 30)	135
Quinidine Sulfate Oral Suspension [ <i>new</i> ] (USP 30)	136
Senna (USP 30)	137
Senna Pods [ <i>new</i> ] (USP 30)	140
Sennosides (USP 30)	141

Simvastatin (USP 30) . . . . .	141
Sumatriptan Succinate Oral Suspension [ <i>new</i> ] (USP 30) . . . . .	144
Temazepam (USP 30) . . . . .	145
Thalidomide (USP 30) . . . . .	146
Thimerosal (USP 30) . . . . .	147
Tizanidine Tablets [ <i>new</i> ] (USP 30) . . . . .	147
Valsartan [ <i>new</i> ] (USP 30) . . . . .	150
Verapamil Hydrochloride Injection (USP 30) . . . . .	154
Verapamil Hydrochloride Oral Solution [ <i>new</i> ] (USP 30) . . . . .	155
Verapamil Hydrochloride Oral Suspension [ <i>new</i> ] (USP 30) . . . . .	156
Verapamil Hydrochloride Tablets (USP 30) . . . . .	158
Zidovudine Tablets (USP 30) . . . . .	158
<b>DIETARY SUPPLEMENTS—MONOGRAPHS</b> . . . . .	<b>160</b>
Ginger (USP 30) . . . . .	160
Powdered Ginger (USP 30) . . . . .	162
Ginger Capsules (USP 30) . . . . .	163
Ginger Tincture (USP 30) . . . . .	163
Ginkgo (USP 30) . . . . .	164
Powdered Ginkgo Extract [ <i>new</i> ] (USP 30) . . . . .	166
Ginkgo Capsules [ <i>new</i> ] (USP 30) . . . . .	172
Ginkgo Tablets [ <i>new</i> ] (USP 30) . . . . .	174
<b>MONOGRAPHS (NF)</b> . . . . .	<b>177</b>
Acetyltributyl Citrate (NF 25) . . . . .	177
Acetyltriethyl Citrate (NF 25) . . . . .	178
Cellulose (NF 25) . . . . .	179
Strawberry Syrup [ <i>new</i> ] (NF 25) . . . . .	179
Tributyl Citrate (NF 25) . . . . .	179
Triethyl Citrate (NF 25) . . . . .	180
<b>GENERAL TEST CHAPTERS</b> . . . . .	<b>181</b>
⟨11⟩ USP Reference Standards (USP 30) . . . . .	181
⟨231⟩ Heavy Metals (USP 30) . . . . .	182
<b>GENERAL INFORMATION CHAPTERS</b> . . . . .	<b>184</b>
⟨2040⟩ Disintegration and Dissolution of Dietary Supplements (USP 30) . . . . .	184
<b>REAGENTS, INDICATORS, AND SOLUTIONS</b> . . . . .	<b>186</b>
<i>Reagent Specifications</i> . . . . .	186
Dextran, High Molecular Weight (USP 30) . . . . .	186
Hydrazine Hydrate, 85% in Water (USP 30) . . . . .	186
1-Naphthol (USP 30) . . . . .	186
<i>p</i> -Toluenesulfonyl-L-arginine Methyl Ester Hydrochloride (USP 30) . . . . .	186
<b>REFERENCE TABLES</b> . . . . .	<b>187</b>
Container Specifications for Capsules and Tablets (USP 30) . . . . .	187
Description and Solubility (USP 30) . . . . .	188
<b>PENDING PROPOSALS</b> . . . . .	<b>190</b>
<b>CANCELED PROPOSALS</b> . . . . .	<b>204</b>
<b>HARMONIZATION</b> . . . . .	<b>207</b>
<b>PHARMACOPEIAL PREVIEWS</b> . . . . .	<b>209</b>
<b>STIMULI TO THE REVISION PROCESS</b> . . . . .	<b>211</b>
Instructions to Authors . . . . .	213
<b>NOMENCLATURE</b> . . . . .	<b>215</b>
<b>INDEX</b> . . . . .	<b>221</b>

## STAFF DIRECTORY

This updated directory reflects assignment changes based on 2005–2010 Expert Committees. The general USP telephone number, (301) 881-0666, may still be used for general inquiries or when a particular Expert Committee is not identified. The fax number is (301) 816-8373.

STAFF	E-MAIL	PHONE	ASSIGNMENT
<b>Clydewyn M. Anthony, Ph.D.,</b> Scientist	cma@usp.org	(301) 816-8139	Monograph Development— Cough, Cold, and Analgesics (MD-CCA)
<b>Shawn C. Becker, BSN.,</b> Director, Patient Safety	scb@usp.org	(301) 816-8216	Safe Medication Use
<b>Daniel K. Bempong, Ph.D.,</b> Scientist	dkb@usp.org	(301) 816-8143	Pulmonary and Steroids (MD-PS)
<b>Lokesh Bhattacharyya, Ph.D.,</b> Director, Non-Complex Actives and Excipients	lb@usp.org	(301) 816-8201	
<b>Barbara A. Bowman,</b> Manager, Administrative Services	bab@usp.org	(301) 816-8278	USP Correspondence
<b>William E. Brown,</b> Senior Scientist	web@usp.org	(301) 816-8380	Biopharmaceutics (BPC); Pharmaceutical Dosage Forms (PDF)
<b>Evelyn Bryant,</b> Manager, Editorial Services	eb@usp.org	(301) 816-8302	
<b>Damian A. Cairatti,</b> Senior Scientific Associate	dac@usp.org	(301) 816-8307	USP Spanish Edition; Dietary Supplements—Bioavailability (DS-BA); Dietary Supple- ments—General Chapters (DS-GC)
<b>Larry N. Callahan, Ph.D.,</b> Scientist	lnc@usp.org	(301) 816-8385	B&B Proteins and Polysaccha- rides (BB PP)
<b>Antonio Hernandez-Cardoso</b> Scientist, Latin American Specialist	ahc@usp.org	(301) 816-8308	USP Spanish Edition; General Chapters (GC)
<b>Todd L. Cecil, Ph.D.,</b> Vice President, Standards Development	tlc@usp.org	(301) 816-8234	
<b>Roger Dabbah, Ph.D.,</b> Scientific Fellow	rd@usp.org	(301) 816-8336	
<b>Behnam Davani, Ph.D.,</b> Senior Scientist	bd@usp.org	(301) 816-8394	Monograph Development— Antivirals and Antimicrobials (MD-AA)
<b>Ian F. DeVeau, Ph.D.,</b> Acting Director, Complex Actives	ifd@usp.org	(301) 816-8178	Biologics and Biotechnology— Blood and Blood Products (BB BBP); Veterinary Drugs (VET); Veterinary Medicine Information (VMI)
<b>Shawn F. Dressman, Ph.D.,</b> Director, Reference Standards Evaluation	sfd@usp.org	(301) 816-8261	Reference Standards (RS)
<b>Lawrence Evans, Ph.D.,</b> Scientist	le@usp.org	(301) 816-8389	Dietary Supplements—General Chapters (DS-GC); Dietary Supplements—Non- Botanicals (DSN)

STAFF DIRECTORY (continued)

STAFF	E-MAIL	PHONE	ASSIGNMENT
<b>L. Valentin Feyns, Ph.D.,</b> Scientific Fellow	lvf@usp.org	(301) 816-8121	Reference Standards (RS)
<b>Gabriel I. Giancaspro, Ph.D.,</b> Associate Director and Latin American Liaison	gig@usp.org	(301) 816-8343	USP Spanish Edition, Dietary Supplements— Botanicals (DSB); Dietary Supplements— General Chapters (DS GC)
<b>Brian D. Gilbert, Ph.D.,</b> Scientist	bg@usp.org	(301) 816-8223	Monograph Development— Antibiotics (MD-ANT)
<b>Elena Gonikberg, Ph.D.,</b> Senior Scientist	eg@usp.org	(301) 816-8251	Gastrointestinal, Renal, and Endocrine (MD-GRE)
<b>Desmond G. Hunt, Ph.D.,</b> Senior Scientific Associate	dgh@usp.org	(301) 816-8341	Packaging and Storage (P&S)
<b>James W. Kelly, Ph.D.,</b> Scientist	jwk@usp.org	(301) 816-8167	Parenteral Products—Industrial (PPI)
<b>Sujatha Kondubhotla, Ph.D.,</b> Scientist	TBD	TBD	Monograph Development— Cardiovascular (MD-CV)
<b>Christina H. Lee, Ph.D.,</b> Senior Scientific Associate	chl@usp.org	(301) 816-8335	Compounding Pharmacy (CRX); Sterile Compounding (SCC)
<b>Angela G. Long,</b> Vice President, Volunteer and Organizational Affairs and Executive Secretariat	agl@usp.org	(301) 816-8382	
<b>Anju K. Malhotra,</b> Manager, Scientific Administration	akm@usp.org	(301) 816-8346	
<b>Ronald G. Manning, Ph.D.,</b> Vice President, Monograph and Reference Standard Development	rgm@usp.org	(301) 816-8562	
<b>Feiwen Mao,</b> Senior Scientific Associate	fm@usp.org	(301) 816-8320	Monograph Development— Ophthalmology, Oncology, and Dermatology (MD-OOD)
<b>Margareth R. Marques, Ph.D.,</b> Senior Scientist and Latin American Liaison	mrm@usp.org	(301) 816-8106	Biopharmaceutics (BPC); Pharmaceutical Dosage Forms (PDF); Chromatographic Reagents
<b>Marcia D. Mayfield,</b> Manager, Monograph Development	mxm@usp.org	(301) 816-8358	
<b>Kevin Moore, Ph.D.,</b> Scientist	TBD	TBD	Harmonization; Monograph Improvement
<b>Tina S. Morris, Ph.D.,</b> Senior Scientist	tsm@usp.org	(301) 816-8397	B&B Vaccines and Virology (BB-VV)
<b>Alan W. Nichols, Ph.D.,</b> Director, Reference Standards Production	awn@usp.org	(301) 816-8321	USP Reference Standards
<b>Claudia C. Okeke, Ph.D.,</b> Associate Director, General Policies and Requirements Division	cco@usp.org	(301) 816-8243	Compounding Pharmacy Sterile Compound- ing (SCC)
<b>Horacio Pappa, Ph.D.,</b> Scientist and Latin American Liaison	hp@usp.org	(301) 816-8319	General Chapters (GC); Statistics (STAT)

## STAFF DIRECTORY (continued)

STAFF	E-MAIL	PHONE	ASSIGNMENT
<b>W. Larry Paul, Ph.D.</b> , Scientific Fellow	wlp@usp.org	(301) 816-8331	Nomenclature (NOM)
<b>David A. Porter, Ph.D.</b> , Director, General Policies and Requirements	dap@usp.org	(301) 816-8225	
<b>Ravi Ravichandran, Ph.D.</b> , Senior Scientist	rr@usp.org	(301) 816-8330	Monograph Development— Psychiatrics and Psychoactives (MD-PP)
<b>Gary E. Ritchie, M.S.</b> , Scientific Fellow for PAT	ger@usp.org	(301) 816-8353	General Chapters (GC); Pharmaceutical Waters (PW); Statistics (STAT)
<b>Karen A. Russo, Ph.D.</b> , Associate Director, Monograph Acquisition and Infrastructure	kar@usp.org	(301) 816-8379	Monograph Acquisition and Infrastructure
<b>Stefan P. Schuber, Ph.D.</b> , Director, Scientific Reports	sps@usp.org	(301) 816-8551	
<b>Maged H. M. Sharaf, Ph.D.</b> , Senior Scientist	mhs@usp.org	(301) 816-8318	Dietary Supplements— Botanicals (DSB); Dietary Supplements— General Chapters (DS-GC)
<b>Catherine M. Sheehan</b> , Scientist	cxs@usp.org	(301) 816-8262	Excipient Monographs 1 (EM1); Excipient General Chapters (EGC); Harmonization
<b>Eric B. Sheinin, Ph.D.</b> , Chief Science Officer	es@usp.org	(301) 816-8103	
<b>Anita Y. Szajek, Ph.D.</b> , Senior Scientist	aey@usp.org	(301) 816-8325	B&B Cell, Gene, and Tissue Therapies (BB CGT)
<b>Radhakrishna S. Tirumalai, Ph.D.</b> , Scientist	rst@usp.org	(301) 816-8339	General Toxicity and Medical Device Biocompatibility (GTMDB); Microbiology and Sterility Assurance (MSA)
<b>Hong Wang, Ph.D.</b> , Senior Scientific Associate	hw@usp.org	(301) 816-8351	Excipient Monographs 2 (EM2); Excipient General Chapters (EGC)
<b>Beryl Voigt</b> , Director, Executive Secretariat	bev@usp.org	(301) 816-8155	
<b>Andrzej Wilk, Ph.D.</b> , Scientist	aw@usp.org	(301) 816-8305	Radiopharmaceuticals and Medical Imaging Agents (RMI); Radiopharmaceutical Information (RI)
<b>Kahkashan Zaidi, Ph.D.</b> , Scientist	kxz@usp.org	(301) 816-8269	Aerosols (AER); General Chapters (GC)

**GENERAL CHAPTERS ⟨1⟩ AND ⟨905⟩ POSTPONEMENTS—CLARIFICATION.** Two postponements that appeared in the *Fifth IRA* and *Sixth IRA* respectively for ⟨1⟩ *Injections*, and ⟨905⟩ *Uniformity of Dosage Units*, do not appear as postponed in the *USP 29–NF 24*. This is due to USP's publication schedule, which slates the *Fifth IRA* and *Sixth IRA* for the *First Supplement* to *USP 29–NF 24*, rather than to the book. The *First Supplement* is scheduled to be published February 15 and official April 1, 2006. The complete publication schedule is available on page 30.

For general chapter ⟨1⟩ *Injections*, USP has postponed the text for *Printing on Ferrules and Cap Overseals* that was to become official on October 1, 2005 as stated in *USP 28–NF 23*. The reason for the postponement is that the Parenteral Products-Industrial, Nomenclature, and Safe Medication Use Expert Committees have approved a revision of this section that also appears in *Pharmacoepial Forum* 31(5) with an implementation date of February 1, 2009.

For general chapter ⟨905⟩ *Uniformity of Dosage Units*, USP has postponed the official date from April 1, 2006 to January 1, 2007, to provide additional time for the Pharmacopeial Discussion Group to evaluate comments received concerning this revision.

Further information about these postponements is available on USP's website ([www.usp.org](http://www.usp.org)). If you have any questions, please contact Beryl Voigt, Director, Executive Secretariat (301-816-8155 or [bev@usp.org](mailto:bev@usp.org)).

**USP ISSUES NOTICE OF RETRACTION FOR RESIDUAL SOLVENTS.** Please note the following retraction notice that has been included on page 14 of the *USP 29–NF 24*.

*“Residual Solvents ⟨467⟩: meet the requirements.” is hereby withdrawn from all monographs in the USP and the NF. This retraction is made to allow the USP Council of Experts further time to evaluate the most appropriate manner to implement the Residual Solvents test. The General Notices statement concerning the application of Residual Solvents to all monographs is unaffected by this retraction.*

*This notice also serves as an additional request for comments on this issue from all users of the USP. Please forward your comments to:*

Todd Cecil, Ph.D.  
Vice President  
Department of Standards Development  
USP  
12601 Twinbrook Parkway  
Rockville, MD 20852

*Comments must be received by June 1, 2006 to ensure consideration.*

**REVISIONS TO GOLDENSEAL MONOGRAPHS.** It is proposed to use Hydrastine free base as the USP Reference Standard because the water sorption analysis showed greater stability than the currently official hydrochloride form. Correction factors are accordingly removed from the procedures. These revisions are proposed to bring the procedures in the monographs in agreement with the free base form of Reference Standard materials already released by USP. Since these revisions do not change the essence of the procedures, they are intended to become official via immediate *Interim Revision Announcement*.

**USP DIRECTOR OF EXECUTIVE SECRETARIAT NAMED.** Beryl E. Voigt has been named the new Director, Executive Secretariat. Ms. Voigt joined USP in 1994 and worked her way up in the Research and Development Laboratory from Senior Chemist II to Senior Group Leader, where she was responsible for the administration of many RDL responsibilities. Prior to joining USP, she served in various chemist positions for pharmaceutical companies in Maryland, Pennsylvania, and New Jersey. Ms. Voigt earned her B.S. in Chemistry with a management option from Carnegie-Mellon University. Ms. Voigt will be responsible for many of the procedural responsibilities for USP Expert Committees and the standards-setting process.

**EXPERT COMMITTEE SUMMARIES AVAILABLE ON THE USP WEBSITE.** Summaries of the first meetings of the cycle for the 2005–2010 Standards Expert Committees are now posted and available at <http://www.usp.org/USPNF/meetingSummaries/>.

**USP ANNOUNCES THE CHAIRS OF THE INFORMATION EXPERT COMMITTEES.** USP is pleased to announce the following individuals who were elected to the USP Council of Experts in September as chairs of Information Expert Committees. Two individuals declined their appointments, resulting in vacancies for the Clinical Toxicology and Nephrology and Urology Expert Committees. Another election to fill these vacancies will take place in the future. Expert Committee members for these Expert Committees will be elected in the Spring of 2006.

Cardiology: Sarah A. Spinler, Pharm.D.; Clinical: Toxicology Vacant; Dermatology: Dennis P. West, Ph.D.; Endocrinology: Karim A. Calis, Pharm.D., M.P.H.; Gastroenterology: Bruce Bacon, M.D.; Hematology: Patrick A. McKee, M.D.; Immunology: John D. Grabenstein,

Ph.D.; Infectious Diseases: Douglas W. MacPherson, M.D.; Nephrology and Urology: Vacant; Neurology/Otorhinolaryngology/Ophthalmology: Mitchell F. Brin, M.D.; Oncology: Barbara A. Burtness, M.D.; Psychiatry: Amy H. Schwartz, Pharm.D., B.C.P.S.; Pulmonary: Elliott Israel, M.D.; Rheumatology: David H. Campen, M.D.; Special Populations/Clinical Pharmacology: Joseph T. Hanlon, Pharm.D.; Therapeutic Decision Making: Nancy Jo Braden, M.D.

**USP SEEKS SUBMISSION OF PROPOSALS FOR STABILITY INDICATING ASSAY PROCEDURES FOR STEROIDS.** The assay procedures for steroids in many *USP–NF* monographs are not stability indicating. In an effort to update the monographs, the Monograph Development—Pulmonary and Steroids Expert Committee is seeking submission of proposals of stability indicating assay procedures for steroids, preferably HPLC- or GC-based, for inclusion in the following *USP–NF* monographs to replace the current procedures that are not stability indicating. The submissions should include data and other information recommended in the *USP Guideline for Submitting Requests for Revision to the USP–NF* at <http://www.usp.org/pdf/EN/USPNF/revisionGuide.pdf>. Each submission should include analytical validation data, data demonstrating that the procedure is stability indicating, and results of analysis from three commercial batches. Please submit proposals for steroid assay procedures for the following *USP–NF* monographs to Daniel Bempong, Ph.D., or contact him for the details at 301-816-8143 or [dkb@usp.org](mailto:dkb@usp.org).

**Drug Substance:**

Clocortolone Pivalate  
Danazol  
Desoxycorticosterone Acetate  
Estriol  
Fludrocortisone Acetate  
Flumethasone Pivalate  
Hydrocortisone Sodium Phosphate  
Hydrocortisone Sodium Succinate  
Hydroxyprogesterone Caproate  
Levonorgestrel  
Meprednisone  
Mestranol  
Methylprednisolone Sodium Succinate  
Nandrolone Phenpropionate  
Norethindrone  
Norethindrone Acetate  
Norethynodrel  
Norgestrel

Oxandrolone  
Oxymetholone  
Paramethasone Acetate  
Prednisolone Hemisuccinate  
Prednisolone Sodium Phosphate  
Testosterone  
Testosterone Enanthate  
Testosterone Propionate

**Dosage Form:**

Betamethasone Oral Solution  
Clocortolone Pivalate Cream  
Desoxycorticosterone Acetate Injection  
Desoxycorticosterone Acetate Pellets  
Dexamethasone Gel  
Dexamethasone Sodium Inhalation Aerosol  
Dexamethasone Tablets  
Dexamethasone Topical Aerosol  
Estradiol Injectable Suspension  
Estradiol Tablets  
Estrone Injection  
Flumethasone Pivalate Cream  
Hydrocortisone Acetate Injectable Suspension  
Hydrocortisone Acetate Ophthalmic Ointment  
Hydrocortisone Acetate Ophthalmic Suspension  
Hydrocortisone Injectable Suspension  
Hydrocortisone Sodium Phosphate Injection  
Hydroxyprogesterone Caproate Injection  
Methylprednisolone Acetate Cream  
Methyltestosterone Capsules  
Methyltestosterone Tablets  
Nandrolone Phenpropionate Injection  
Norethindrone Acetate Tablets  
Norethindrone Acetate and Ethinyl Estradiol Tablets (assay for both steroids)  
Norethindrone Tablets  
Norgestrel Tablets  
Oxymetholone Tablets  
Paramethasone Acetate Tablets  
Penicillin G Procaine, Dihydrostreptomycin Sulfate, and Prednisolone Injectable Suspension (assay for Prednisolone)  
Neomycin Sulfate, Sulfacetamide Sodium, and Prednisolone Acetate Ophthalmic Ointment (assay for Prednisolone Acetate)  
Prednisolone Sodium Phosphate Injection  
Prednisolone Sodium Phosphate Ophthalmic Solution  
Neomycin Sulfate and Prednisolone Sodium Phosphate Ophthalmic Ointment (assay for Prednisolone Sodium Phosphate)

Prednisolone Sodium Succinate for Injection  
 Prednisolone Cream  
 Progesterone Intrauterine Contraceptive System  
 Testosterone Enanthate Injection  
 Testosterone Injectable Suspension  
 Testosterone Propionate Injection

drug substances and drug products that are, or soon will be, off patent and thus are of the highest priority. USP also is seeking monographs for the excipients listed below (updated as of September 1, 2005). Monograph sponsors should consult the *USP Guideline for Submitting Requests for Revision to the USP–NF* at <http://www.usp.org/pdf/EN/USPNF/revisionGuide.pdf>.

**CALL FOR HIGH PRIORITY MONOGRAPHS FOR DRUG SUBSTANCES AND PRODUCTS AND EXCIPIENTS.** USP is seeking monographs for the following

**For further information, contact Karen Russo, Ph.D., [kar@usp.org](mailto:kar@usp.org).**

**Noncomplex Actives (Drug Substances)**

Acarbose	Alatrofloxacin Mesylate	Alfuzosin
Allopurinol Sodium	Aminopromazine Fumarate	Aminopterin Sodium
Amlodipine	Anagrelide Hydrochloride <i>(Received)</i>	Arsenic Trioxide
Azelaic Acid	Balsalazide Disodium	Bentoquatam
Bepriidil Hydrochloride	Bicalutamide <i>(Received)</i>	Bivalirudin
Budesonide <i>(Received)</i>	Cabergoline	Calcipotriene
Calcium Trisodium Pentetate	Calfactant	Candesartan Cilexetil
Carmustine	Carvedilol	Cefdinir
Cefditoren Pivoxil	Ceftibuten	Cetirizine Hydrochloride <i>(Received)</i>
Cetorelix	Cevimeline	Chloroxine
Cilostazol <i>(Received)</i>	Citalopram Hydrobromide <i>(Received)</i>	Colfosceril
Cytarabine Liposome	Dalfopristin	Dantrolene Sodium <i>(Received)</i>
Dapirazole Hydrochloride	Desirudin	Dexrazoxane
Didanosine <i>(Received)</i>	Difloxacin Hydrochloride	Divalproex Sodium <i>(Received)</i>
Docosanol	Entacapone	Epoprostenol
Erythromycin Phosphate	Erythromycin Thiocyanate	Esomeprazole Magnesium
Esmolol	Estazolam	Estramustine Phosphate Sodium
Estradiol Benzoate	Ethanolamine Oleate	Etomidate
Etoposide Phosphate	Exemestane	Felbamate
Fentanyl <i>(Received)</i>	Fluoromethane F 18	Foscarnet Sodium
Fosfomycin Tromethamine	Gadobenate Dimeglumine	Galantamine Hydrobromide
Gadopentetic Acid	Gallium Nitrate	Ganirelix
Glyceryl Aminobenzoate	Granisetron	Halobetasol Propionate
Haloperidol Decanoate <i>(Received)</i>	Hydrocodone Polistirex	Hydrocortisone <i>(Received)</i>
Ibandronate Sodium	Imipramine Pamoate	Imiquimod
Irinotecan	Isosulfan Blue	Itraconazole
Lamotrigine <i>(Received)</i>	Latanoprost	Lawson
Levetiracetam	Levobetaxolol	Levocabastine Hydrochloride <i>(Received)</i>
Levofloxacin <i>(Received)</i>	Levomethadyl Acetate	Lomustine
Lopinavir	Metipranolol Hydrochloride	Midazolam Hydrochloride
Miglitol	Mifepristone	Misoprostol <i>(Received)</i>
Mivacurium	Moexipril	Nalbuphine Hydrochloride
Nalmefene Hydrochloride	Nateglinide	Nedocromil
Nicardipine Hydrochloride	Nilutamide	Nisoldipine
Olopatadine	Olsalazine Sodium	Orbifloxacin
Orlistat <i>(Received)</i>	Oxcarbazepine <i>(Received)</i>	Pancuronium Bromide <i>(Received)</i>
Pantoprazole Sodium	Pemoline	Pentamidine Isethionate
Piperonyl Butoxide	Pirbuterol Acetate	Poractant Alpha
Prednicarbate <i>(Received)</i>	Proguanil	Quetiapine Fumarate

Noncomplex Actives (Drug Substances) (Continued)

Risperidone ( <i>Received</i> )	Rose Bengal	Salmeterol Xinafoate
Sodium Phenylbutyrate	Simethicone Powder	Sterile Methotrexate Sodium
Streptozocin	Sulfacytine	Tacrolimus
Terbinafine Hydrochloride	Terconazole	Tiludronate Disodium
Tiopronin	Tranexamic Acid	Trimipramine Maleate
Trovafloxacin Mesylate	Voriconazole	Zinc Tridosium Pentetate

Noncomplex Actives (Drug Products)

Abacavir Sulfate, Lamivudine, and Zidovudine Tablets	Acarbose Tablets	Acetaminophen, Butalbital, Caffeine, and Codeine Phosphate Capsules
Acetaminophen, Clemastine Fumarate and Pseudoephedrine Hydrochloride Tablets	Acetazolamide Extended-Release Capsules	Albuterol Extended-Release Tablets
Albuterol for Inhalation	Albuterol Inhalation Aerosol	Alendronate Sodium Oral Solution
Alfuzosin Tablets	Allopurinol For Injection	Alprazolam Extended-Release Tablets
Alprostadil Urethral Suppository	Aminopromazine Fumarate and Neomycin Sulfate Tablets	Aminopromazine Fumarate Injection
Aminopromazine Fumarate Tablets	Amlodipine and Benazepril Hydrochloride Capsules	Aminopterin Sodium Tablets
Amphotericin B Injection	Anagrelide Hydrochloride Capsules	Arsenic Trioxide Injection
Atovaquone and Proguanil Hydrochloride Tablets	Atovaquone Tablets	Auranofin Capsules
Azatadine Maleate and Pseudoephedrine Sulfate Extended-Release Tablets	Azelaic Acid Cream	Azithromycin for Injection
Azithromycin Tablets	Baclofen Injection	Balsalazide Disodium Capsules
Beclomethasone Dipropionate Inhalation Aerosol	Beclomethasone Dipropionate Metered-Dose Nasal Suspension	Bentoquatam Topical Suspension
Benzocaine and Cetylpyridinium Chloride Lozenges	Benzocaine and Menthol Lotion	Benzphetamine Hydrochloride Tablets
Bepiridil Tablets	Bicalutamide Tablets	Brompheniramine Maleate, Dextromethorphan Hydrobromide and Pseudoephedrine Hydrochloride Oral Solution
Bivalirudin Injection	Budesonide Metered-Dose Inhalation Aerosol	Budesonide Inhalation Aerosol
Bupivacaine and Lidocaine Hydrochlorides Injection	Buprenorphine Hydrochloride Injection	Butalbital and Acetaminophen Capsules
Butalbital and Acetaminophen Tablets	Butorphanol Tartrate Nasal Solution ( <i>Received</i> )	Calcipotriene Topical Solution Cabergoline Tablets
Calcipotriene Cream	Calcipotriene Ointment	Calcitriol Capsules
Calcitriol Oral Solution	Calcium Acetate Capsules	Calfactant Intratracheal Suspension
Calcium Trisodium Pentetate Injection	Carbidopa and Levodopa Extended-Release Tablets	Carbidopa and Levodopa Tablets for Oral Suspension
Carbidopa, Levidopa, and Entacapone Tablets	Carmustine Implant	Carmustine for Injection
Carvedilol Tablets	Cefditoren Pivoxil Tablets	Cefdinir Tablets
Ceftibuten Capsules	Ceftibuten for Oral Suspension	Cetirizine Hydrochloride Oral Solution
Ceftiofur Hydrochloride Oral Suspension	Cetrorelix Injection	Cetirizine Hydrochloride Tablets
Cevimeline Hydrochloride Capsules	Choline and Magnesium Salicylates Oral Solution	Chloroxine Cream
Chlorpromazine Hydrochloride Extended-Release Capsules	Ciclopirox Shampoo	Choline and Magnesium Salicylates Tablets
Choline Salicylate Oral Solution	Ciclopirox Topical Gel	Ciclopirox Topical Solution
Ciprofloxacin Hydrochloride and Hydrocortisone Otic Suspension	Cilostazol Tablets	Cimetidine Oral Solution

## Noncomplex Actives (Drug Products) (Continued)

Citalopram Hydrobromide Oral Solution	Citalopram Hydrobromide Tablets <i>(Received)</i>	Ciprofloxacin Otic Solution
Cladribine Injection	Citric Acid, Gluconolactone, and Magnesium Carbonate Irrigation	Clonazepam Orally-Disintegrating Tablets
Clemastine Fumarate Syrup	Clobetasol Propionate Gel	Clotrimazole and Betamethasone Dipropionate Lotion
Clorazepate Dipotassium Capsules	Clorazepate Dipotassium Extended-Release Tablets	Colfosceril and Tyloxapol Suspension
Colestipol Hydrochloride Tablets	Conjugated Estrogens and Medroxyprogesterone Acetate Tablets	Compound Undecylenic Acid Cream
Compound Undecylenic Acid Topical Powder	Cyclosporine Modified Oral Solution	Cromolyn Sodium Metered-Dose Nasal Solution
Cyclosporine Modified Capsules	Cysteamine Bitartrate Capsules	Cyclosporine Ointment
Cyclosporine Topical Solution	Cytarabine Liposome Injection	Dantrolene Sodium Capsules <i>(Received)</i>
Dalfopristin and Quinupristin Injection	Dapiprazole for Ophthalmic Solution	Dantrolene Sodium for Injection <i>(Received)</i>
Dantrolene Sodium Oral Suspension	Desirudin for Injection	Desonide <i>(Received)</i>
Desonide Cream	Dexrazoxane for Injection	Dextroamphetamine Sulfate Extended-Release Capsules
Dextromethorphan Polistirex Extended-Release Oral Suspension	Diazepam Injectable	Diclofenac Sodium Ophthalmic Solution
Didanosine Chewable Tablets <i>(Received)</i>	Didanosine for Oral Solution <i>(Received)</i>	Diethylpropion Hydrochloride Extended-Release Tablets
Difenoxin and Atropine Tablets	Difloxacin Hydrochloride Tablets	Dihydroergotamine Mesylate Metered Spray
Diltiazem Malate Extended-Release Tablets	Dinoprostone Vaginal Suppositories	Diphenhydramine Hydrochloride and Acetaminophen Tablets
Divalproex Sodium Delayed-Release Capsules	Dorzolamide and Timolol Ophthalmic Solution	Dorzolamide Ophthalmic Solution
Doxacurium Chloride Injection	Doxepin Hydrochloride Cream	Doxycycline Oral Gel
Econazole Nitrate Cream	Edrophonium Chloride and Atropine Sulfate Injection	Emulsion
Enalaprilat Injection	Enalapril Maleate and Diltiazem Malate Extended-Release Tablets	Enalapril Maleate and Felodipine Extended-Release Tablets
Entacapone Tablets	Ephedrine Sulfate and Guaifenesin Tablets	Epoprostenol for Injection
Epoprostenol Injection	Esmolol Hydrochloride Injection	Esomeprazole Magnesium Capsules
Estazolam Tablets	Estramustine Phosphate Sodium Capsules	Ethanolamine Oleate Injection
Etomidate Injection	Etidronate Disodium Injection Concentrate	Exemestane Tablets
Famotidine Injection <i>(Received)</i>	Famotidine Orally Disintegrating Tablets	Felbamate Oral Suspension
Felbamate Tablets	Fentanyl Lozenges	Fentanyl Transdermal System
Ferrous Fumarate and Docusate Sodium Extended-Release Capsules	Flavoxate Hydrochloride	Flavoxate Hydrochloride Tablets
Fluconazole Injection	Flunisolide Nasal Spray	Fluconazole Tablets
Flunisolide Inhalation Aerosol	Fluocinolone Acetonide Shampoo	Fluorescein Sodium Ophthalmic Solution
Fluticasone Propionate Inhalation Powder	Fluorometholone Ointment	Fluticasone Propionate Cream <i>(Received)</i>
Fluticasone Propionate Ointment <i>(Received)</i>	Fluticasone Propionate Pressurized Inhaler	Foscarnet Sodium Injection
Fosfomycin for Oral Solution	Gabapentin Oral Solution	Gabapentin Tablets
Gadobenate Dimeglumine Injection	Gallium Nitrate Injection	Galantamine Hydrobromide Tablets
Ganirelix Acetate Injection	Ganciclovir Capsules	Gentamicin Sulfate Oral Solution
Gatifloxacin Injection	Gatifloxacin Tablets	Glipizide Extended-Release Tablets
Gentamicin Sulfate Soluble Powder	Glimepiride Tablets	Granisetron Tablets
Granisetron Injection	Guaifenesin and Pseudoephedrine Hydrochloride Extended-Release Tablets	Guaifenesin and Salts of Dextromethorphan and Pseudoephedrine Oral Solution

Noncomplex Actives (Drug Products) (Continued)

Guanidine Hydrochloride	Guanidine Hydrochloride Tablets	Halobetasol Propionate Ointment
Halobetasol Propionate Cream	Haloperidol Decanoate Injection	Haloperidol Lactate Injection
Haloperidol Lactate Oral Concentrate	Hydrochlorothiazide Oral Solution Concentrate	Hydrocodone Bitartrate and Acetaminophen Oral Solution
Hydralazine Hydrochloride and Hydrochlorothiazide Capsules	Hydrocodone Bitartrate and Homatropine Methylbromide Syrup	Hydrochlorothiazide Capsules
Hydrocodone Bitartrate and Guaifenesin Oral Solution	Hydrocodone Bitartrate and Aspirin Tablets	Hydrocortisone Butyrate Lotion
Hydrocodone Bitartrate and Homatropine Methylbromide Tablets	Hydrocortisone Acetate Rectal Foam Aerosol	Hydroquinone Lotion
Hydrocortisone Acetate Dental Paste	Hydroflumethiazide and Reserpine Tablets	Hydromorphone Hydrochloride Oral Solution
Ibuprofen Capsules	Ibandronate Sodium Tablets	Idarubicin Hydrochloride Injection
Imipramine Pamoate Capsules	Imiquimod Topical Cream	Ipratropium Bromide Inhalation Aerosol
Ipratropium Bromide Inhalation Solution	Irinotecan Hydrochloride Injection	Isosulfan Blue Injection
Isradipine Extended-Release Tablets	Itraconazole Injection	Itraconazole Oral Solution
Ketoconazole Cream	Ketoconazole Shampoo	Ketoprofen Capsules
Ketoprofen Extended-Release Capsules	Ketotifen Fumarate	Ketotifen Fumarate Ophthalmic Solution
Ketoprofen Tablets	Lactic Acid Lotion	Lamivudine Tablets
Latanoprost Ophthalmic Solution	Levetiracetam Tablets	Levobetaxolol Ophthalmic Suspension
Levocabastine Ophthalmic Suspension	Leucovorin Calcium for Injection	Levomethadyl Acetate Hydrochloride Oral Concentrate
Levofloxacin Solution	Lidocaine and Prilocaine Cream <b>(Received)</b>	Lincomycin Hydrochloride and Spectinomycin Sulfate Soluble Powder
Liothyronine Injection	Lisinopril and Hydrochlorothiazide Tablets	Lomustine Capsules
Lopinavir Capsules	Lopinavir Solution	Lopinavir and Ritonavir Solution
Loratadine and Pseudoephedrine Sulfate Extended-Release Tablets <b>(Received)</b>	Loratadine Orally-Disintegrating Tablets	Losartan Potassium Tablets
Mesalamine Suppositories	Methacholine Chloride for Inhalation Solution	Mesoridazine Besylate Concentrate
Mefloquine Hydrochloride Tablets	Methoxsalen Softgels	Methadone Hydrochloride Oral Concentrate
Melphalan for Injection	Metaraminol Bitartrate Injection	Methyclothiazide and Deserpidine Tablets
Methocarbamol and Aspirin Tablets	Metipranolol Ophthalmic Solution	Metronidazole Cream
Metronidazole Lotion	Metronidazole Extended-Release Tablets	Methylphenidate Hydrochloride Chewable Tablets
Metronidazole Capsules	Midazolam Hydrochloride Injection	Metronidazole Hydrochloride for Injection
Miconazole Nitrate Topical Aerosol	Mifepristone Tablets	Miglitol Tablets
Milrinone Injection	Misoprostol Dispersion <b>(Received)</b>	Misoprostol Tablets <b>(Received)</b>
Mivacurium in Dextrose Injection	Mivacurium Injection	Moexipril Hydrochloride and Hydrochlorothiazide Tablets
Moexipril Hydrochloride Tablets	Molindone Hydrochloride Oral Solution	Morphine Sulfate for Injection Concentrate
Morphine Sulfate Oral Solution	Morphine Sulfate Oral Solution Concentrate	Morphine Sulfate Tablets
Mycophenolate Mofetil Tablets	Mycophenolate Mofetil Oral Solution	Mycophenolate Mofetil Capsules
Nalbuphine Hydrochloride Injection	Naproxen Extended-Release Tablets	Naphazoline Hydrochloride and Pheniramine Maleate Ophthalmic Solution
Naphazoline Hydrochloride and Pheniramine Maleate Ophthalmic Solution	Nalmefene Hydrochloride Injection	Nateglinide Tablets
Nedocromil Sodium Inhalation Aerosol	Neomycin Sulfate Oral Powder	Nevirapine Oral Suspension <b>(Received)</b>
Nevirapine Tablets <b>(Received)</b>	Nicardipine Hydrochloride Capsules	Nilutamide Tablets
Nimodipine Capsules	Nisoldipine Extended-Release Tablets	Nitroglycerin Solution In Acrylic Adhesive
Nizatidine Tablets	Ofloxacin Injection	Ofloxacin in Dextrose Injection
Ofloxacin Tablets <b>(Received)</b>	Olopatadine Ophthalmic Solution	Olsalazine Sodium Capsules
Ondansetron Oral Solution	Ondansetron Tablets	Orbifloxacin Tablets
Orlistat Capsule <b>(Received)</b>	Orphenadrine Citrate, Aspirin, and Caffeine Tablets	Orphenadrine Citrate Extended Release Tablets

## Noncomplex Actives (Drug Products) (Continued)

Oxcarbazepine Suspension	Oxcarbazepine Tablets	Oxiconazole Cream
Pancuronium Bromide Injection (Received)	Pantoprazole Sodium Tablets	Pantoprazole Sodium for Injection
Paroxetine Hydrochloride Extended-Release Tablets	Paroxetine Oral Suspension	Pemirolast Potassium Ophthalmic Solution
Pemoline Tablets	Penicillin G Potassium Tablets for Oral Solution	Pentaerythritol Tetranitrate Extended-Release Capsules
Pentaerythritol Tetranitrate Extended-Release Tablets	Pentamidine Isethionate for Inhalation	Pentamidine Isethionate for Injection
Pentazocine Hydrochloride and Acetaminophen Tablets	Permethrin Cream (Received)	Phendimetrazine Tartrate Extended-Release Capsules
Phenobarbital Capsules	Phentermine Resin Complex	Phenylephrine Hydrochloride and Chlorpheniramine Maleate Extended-Release Capsules
Phenylephrine Hydrochloride, Chlorpheniramine Maleate, and Acetaminophen Extended-Release Tablets	Phentermine Resin Complex Capsules	Phosphate Oral Solution
Pilocarpine Hydrochloride Ophthalmic Gel	Pilocarpine Hydrochloride Ophthalmic Ointment	Pilocarpine Hydrochloride Tablets
Piperonyl Butoxide and Pyrethrins Aerosol Foam	Pirbuterol Acetate Inhalation Aerosol	Povacrylate Solution
Poractant Alpha Suspension	Porfimer Sodium for Injection	Povacrylate-Iodine Topical Solution
Povidone-Iodine Gauze	Povidone-Iodine Swabsticks	Povidone-Iodine Topical Aerosol Foam
Povidone-Iodine Vaginal Suppositories	Pramipexole Dihydrochloride Tablets	Prazosin Hydrochloride and Polythiazide Capsules
Prednicarbate Cream (Received)	Prednicarbate Ointment (Received)	Prednisolone Sodium Phosphate Oral Solution
Prochlorperazine Maleate Extended-Release Capsules	Progesterone Capsules	Promethazine Hydrochloride and Codeine Phosphate Oral Solution
Promethazine Hydrochloride and Dextromethorphan Hydrobromide Syrup	Promethazine and Phenylephrine Hydrochlorides and Codeine Phosphate Syrup	Promethazine and Phenylephrine Hydrochlorides Syrup
Propafenone Hydrochloride Tablets	Pseudoephedrine Hydrochloride and Brompheniramine Maleate Extended-Release Tablets	Pseudoephedrine Hydrochloride and Naproxen Sodium Extended-Release Tablets
Pseudoephedrine Hydrochloride, Chlorpheniramine Maleate, and Codeine Phosphate Oral Solution	Pseudoephedrine Hydrochloride, Guaifenesin, and Codeine Phosphate Oral Solution	Pseudoephedrine Sulfate and Dexbrompheniramine Maleate Extended-Release Tablets Pyrilamine Maleate Injection
Pseudoephedrine Sulfate and Dexbrompheniramine Maleate Oral Solution	Pseudoephedrine Sulfate, Dexbrompheniramine Maleate, and Acetaminophen Extended-Release Tablets	Quinidine Sulfate Injection
Ramipril Capsules	Ranitidine Capsules	Rauwolfia Serpentina and Endroflumethiazide Tablets
Reserpine and Polythiazide Tablets	Rimantadine Hydrochloride Oral Solution	Risperidone Oral Solution
Risperidone Orally-Disintegrating Tablets	Risperidone Tablets	Rivastigmine Tartrate Capsules
Rivastigmine Tartrate Oral Solution	Rocuronium Bromide Injection	Ropinirole Hydrochloride Tablets
Rose Bengal Ophthalmic Solution	Rosiglitazone Maleate Tablets	Salicylic Acid and Sulfur Cleansing Lotion
Salicylic Acid and Sulfur Lotion	Salicylic Acid and Sulfur Shampoo	Salicylic Acid Cream
Salicylic Acid Ointment	Salmeterol Inhalation Aerosol	Salmeterol Xinafoate Inhalation Powder
Scopolamine Transdermal System	Selegiline Hydrochloride Capsules	Serpaewa Topical Cream
Sertraline Hydrochloride Oral Solution	Sibutramine Hydrochloride Capsules	Sodium Bicarbonate and Sodium Citrate for Oral Solution
Sodium Bicarbonate, Sodium Citrate, and Sodium Tartrate for Oral Suspension	Sodium Chlorophyllin Copper Complex Tablets	Sodium Iodide Injection
Sodium Phenylbutyrate Oral Powder	Sodium Phenylbutyrate Tablets	Sodium Phosphates for Oral Suspension
Sodium Phosphates Tablets	Sodium Salicylate and Sulfur Shampoo	Sterile Talc Aerosol
Streptozocin for Injection	Sucralfate Oral Suspension	Sulconazole Nitrate Cream
Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution	Sulfacetamide Sodium and Fluorometholone Ophthalmic Suspension	Sulfacytine Tablets
Sulfanilamide Vaginal Cream	Sulfasalazine Oral Suspension	Sumatriptan Tablets

Noncomplex Actives (Drug Products) (Continued)

Sulisobenzone Lotion	Sumatriptan Injection	Tacrolimus Capsules
Tacrolimus Ointment	Tacrolimus Injection	Tamsulosin Hydrochloride Capsules
Technetium Tc 99m Teboroxime Injection	Tenofovir Disoproxil Fumarate Tablets	Terbinafine Hydrochloride Cream
Terbinafine Tablets	Terbinafine Topical Solution	Terconazole Vaginal Cream
Terconazole Vaginal Suppositories	Testosterone Transdermal System	Tetracycline Hydrochloride Periodontal Fiber
Theophylline Extended-Release Tablets	Tioconazole Vaginal Ointment	Tiopronin Tablets
Tolnaftate Topical Aerosol Solution	Topiramate Capsules	Topiramate Tablets
Torsemide Injection	Torsemide Tablets	Trandolapril and Verapamil Hydrochloride Extended-Release Tablets
Trandolapril Tablets	Tranexamic Acid Injection	Tranlycypromine Sulfate
Tranlycypromine Sulfate Tablets	Tretinoin Capsules	Tretinoin Microsphere Gel
Triamcinolone Acetonide Metered-Dose Nasal Suspension	Trifluridine Ophthalmic Solution	Trimetrexate for Injection
Trimipramine Maleate Capsules	Tripolidine and Pseudoephedrine Hydrochlorides and Codeine Phosphate Syrup	Trolamine Salicylate Cream
Trolamine Salicylate Gel	Trolamine Salicylate Topical Emulsion	Trovaflaxacin Injection
Trovaflaxacin Mesylate for Injection	Undecylenic Acid Topical Foam Aerosol	Unoprostone Isopropyl Ophthalmic Solution
Urea Cream	Valproic Acid Injection ( <i>Received</i> )	Vecuronium Bromide for Injection
Venlafaxine Extended-Release Capsules	Venlafaxine Tablets	Verapamil Hydrochloride Capsules
Verapamil Hydrochloride Extended-Release Capsules	Voriconazole Injection	Voriconazole Oral Suspension
Voriconazole Tablets	Yttrium Y-90 Chloride Solution	Yttrium Y-90 Glass Microspheres
Yttrium Y-90 Microspheres Injection	Ziprasidone Hydrochloride Capsules	Zidovudine and Lamivudine Tablets
Zinc Acetate Capsules	Zoledronic Acid for Injection	Zinc Tridosium Pentetate Injection

Excipients

Acetone Sodium Bisulfite	Acetylated Monoglycerides	N-Acetyl-L-Methionine
Aconitic Acid (Achilleic Acid)	Acrylic Acid-Octyl Acrylate Copolymer	Albumin Colloidal
Aliphatic Polyesters	Aluminum Ammonium Sulfate	Aluminum Hydroxide
Aluminum Lactate	Aluminum Oxide	Aluminum Ammonium Sulfate
Aluminum Potassium Sulfate	Aluminum Silicate	Aluminum Sodium Sulfate
Aluminum Stearate	Allantoin-Sodium Pyrrolidone Carboxylate	Ammonium Bicarbonate
Ammonium Calcium Alginate	Ammonium Phosphate	L-Ascorbyl Stearate
L-Asparagine	Batylalcohol Monostearate	Beeswax, Synthetic
Benzododecinium Bromide	Benzyl Chloride	Benzyl Nicotinate
Brominated Vegetable Oil	Butadiene-Styrene Rubber	Beta Naphthol
Butylene Glycol	Butylphthalyl Butylglycolate	Butylated Hydromethylphenol
Calcium Alginate	Calcium Alginate and Ammonium Alginate	Calcium Acid Pyrophosphate
Calcium Chloride Solution	Calcium Glycerophosphate ( <i>Received</i> )	Calcium Bromide
Calcium Phosphate Dibasic, Monohydrate	Calcium Phosphate Monobasic	Calcium Phosphate Dibasic, Anhydrous
Calcium Pyrophosphate	Calcium Sorbate	Calcium Propionate
Calcium Sulfate Dihydrate	Calcium Sulfate, Anhydrous	Calcium Stearoyl Lactylate
Calteridol Calcium	Canola Oil	Caldiamide Sodium
Caprylic/Capric Diglyceril Succinate	Carbon	Capric Acid
Carboxymethylamylopectin Sodium	Carboxymethylcellulose Potassium	Carboxymethyl Starch
Cetostearyl Isononanoate	Cholic Acid	Cinnamaldehyde
Chlorodifluoroethane	Cocamide Diethanolamine	Cocamide Oxide
Coconut Oil Hydrogenated	Cocoyl Caprylocaprate	Coconut Oil
Crystal Gum	Cutina	Copper Sulfate
L-Cysteine Monohydrochloride	Dammar Gum	Cystine

## Excipients (Continued)

Decanoic Acid	Decyl Oleate	Dehydroacetic Acid
Desoxycholic Acid	Dextrin Palmitate	Dextrins Modified
Diacetyl Tartaric Acid Esters of Mono- and Diglycerides	Dicetyl Phosphate	Dichlorofluoromethane
Diethylene Glycol Monopalmitostearate	Diethyl Sebacate	Difluoroethane
Diglycol Stearate	Diisopropanolamine ( <i>Received</i> )	Diisobutyl Adipate
Diisopropyl Adipate	Diisopropylbenzothiazyl-2-Sulfenamide	Dilauryl Thiodipropionate
Dimethyl Dicarboxylate	Dimyristoyl Lecithin	Dimyristoyl Phosphatidylglycerol
Diethyl Sodium Sulfosuccinate	Dipropylene Glycol	Disodium Edisylate
Disodium Guanylate	Disodium Inosinate	Disodium Monooleamide Sulfasuccinate
Docusate Sodium/Sodium Benzoate	Erythritol ( <i>Received</i> )	Erythorbic Acid
Erythrosine	Ethoxylated Mono- and Diglycerides	Ethoxyquin
Ethyl Hexanediol	Ethyl Linoleate	Ethyl Maltol
Ethylene Dichloride	Ethylene Glycol Monopalmitostearate	Ethylurea
Ferric Ammonium Citrate	Ferric Citrate	Ferric Oxide, Brown
Ferric Phosphate	Ferric Pyrophosphate	Ferrous Citrate
Ferrous Glycinate	Ferrous Lactate	Fluorochlorohydrocarbons
Formic Acid	Furcelleran	Gamma-Cyclodextrin
Gentistic Acid	Geraniol	L-Glutamic Acid
Glutamic Acid Hydrochloride	Gluten	Glycerol Ester of Gum Rosin (Ester Gum)
Glyceryl Laurate	Glyceryl Palmitate	Glyceryl Ricinoleate
Glyceryl Tristearate	Glycine Hydrochloride	Glycofurool
Glycol Stearate	Heptafluoropropane	Heptylparaben
Hexadecyl Isostearate	Hexane	Hexanetriol(-1,2,6-)
Hydrocarbon Gel	Hydrogenated Starch Hydrolysate	Hydroxyethylmethylcellulose
Hydroxylated Lecithin	Hydroxypropyl Beta Cyclodextrin	Indigotine
Inositol	Iron Carbonyl	Iron Subcarbonate
Isobutylated-Isoprene Copolymer	Isooctylacrylate	Isopropyl Isostearate
Isopropyl Stearate	Isostearic Acid	Isostearyl Alcohol
Lactobionic Acid	Lactose Ferrin, Bovine	Lactylated Fatty Acid Esters of Glycerol and Propylene Glycol
Lactylic Esters of Fatty Acids	Lanolin Anhydrous	Lanolin Alcohols, Acetylated
Lanolin (Wool Fat), Hydrogenated	Lanolin Hydrous	Lauramine Oxide
Lauric Acid	Lauric Diethanolamide	Lauric Myristic Diethanolamide
Lavender Oil	Lecithin, Hydroxylated	L-Leucine
Linoleic Acid	Macrogol Lauryl Ether	Macrogol Oleate
Macrogol Sorbitan Tristearate	Macrogol Stearyl Ether	Macrogolglycerol Cocoates
Macrogolglycerol Triisostearate	Magnesium Aluminum Silicate Hydrate	Magnesium Aspartate
Magnesium Aspartame Dihydrate	Magnesium Phosphate, Dibasic, Trihydrate	Magnesium Phosphate Tribasic
Magnesium Tartrate	Maltitol ( <i>Received</i> )	Maltitol Syrup
Maltol Isobutyrate	Malt Syrup	Manganese Chloride
Manganese Citrate	Manganese Glycerophosphate	Manganese Hypophosphate
D-Mannose	Medical Antifoam Emulsion C	Medronate Disodium
Medronic Acid	Methyl Chloride	Methylchloroisothiazolinone
Methyl Hydroxyethyl Cellulose	Methylisothiazolinone	N-Methylpyrrolidone ( <i>Received</i> )
Microcrystalline Cellulose, Silicified ( <i>Received</i> )	Mineral Spirits	Monoisostearyl Glyceryl Ester
Monopotassium Glutamate Monohydrate	Monosodium Citrate	Mullein Leaf
Myristyl Gamma-Picolinium Chloride	Myristyl Lactate	N,N-Bis(2-Hydroxyethyl)Stearamide
Naphtha	Non-Pareil Seeds	Nutmeg Oil
Octanoic Acid	Oleyl Oleate ( <i>Received</i> )	Oxystearin
Palm Kernel Oil	Palm Oil	Pentasodium Triphosphate
Pentetate Calcium Trisodium	Pentetate Pentasodium	Phenprobamate

Excipients (Continued)

Phenylmercuric Borate	Pine Oil	Polacrillin
Polyacrylate Dispersion 30 Percent (Received)	Polydextrose	Polydextrose Solution
Polyglycerol Esters of Fatty Acids	Polyglycerol Polyricinoleic Acid	Polyoxyethylene Castor Oil (USP has 35)
Polyoxyl Stearate (USP has 40)	Polypropylene Oleate	Polyvinyl Acetate
Polyvinylacetal	Polyvinylacetal Diethylanoacetate	Polyvinylpyrrolidone
Polypropylene Stearyl Ether	Polyvinylpyrrolidone Ethylcellulose	Polysorbate 65
Potassium Acid Tartrate	Potassium Alginate (Received)	Potassium Bromate
Potassium Carbonate Solution	Potassium Dichloroisocyanurate	Potassium Gibberellate
Potassium Glycerophosphate	Potassium Iodate	Potassium Nitrite
Potassium Phosphate	Potassium Phosphate Tribasic	Potassium Polymetaphosphate
Potassium Pyrophosphate	Potassium Stearate	Potassium Sulfate
Potassium Sulfite	Potassium Tripolyphosphate	Propylene Glycol Diacetate
Propylene Glycol Mono- and Diesters	Propylene Glycol Monolaurate (Received)	Propyl Propionate
Purified Polyoxyl 35 Castor Oil (Received)	Rapeseed Oil, Hydrogenated	Rapeseed Oil, Superglycerinated
Rice Bran Wax	Rosin	Silicone
Sodium Acid Pyrophosphate	Sodium Aluminosilicate	Sodium Aluminum Phosphate Acidic
Sodium Aluminum Phosphate Basic	Sodium Aspartate	Sodium Bisulfate
Sodium Bisulfite	Sodium Carbonate Hydrate	Sodium Carboxymethyl Betaglucon
Sodium Caseinate	Sodium Chlorate	Sodium Citrate, Dibasic
Sodium Citrate, Monobasic	Sodium Cyclamate	Sodium Dehydroacetate
Sodium Diacetate	Sodium Erythorbate	Sodium Ferric Pyrophosphate
Sodium Ferrocyanide	Sodium Hypophosphite	Sodium Laureth Sulfate
Sodium Lauroyl Sarcosinate	Sodium Lauryl Sulfoacetate	Sodium Magnesium Aluminosilicate
Sodium Magnesium Silicate	Sodium Malate	Sodium Metaphosphate, Insoluble
Sodium Metasilicate	Sodium Methylate	Sodium Polyphosphates Glassy
Sodium Potassium Tripolyphosphate	Sodium Pyrophosphate	Sodium Pyrrolidone Carboxylate
Sodium Sesquicarbonate	Sodium Sesquinoleate	Sodium Stearoyl Lactylate
Sodium Thiomalate	Sodium Trimetaphosphate	Sodium Trioleate
Sodium Tripolyphosphate	Soy Polysaccharides	Stannous Chloride
Stannous Tartrate	Starch, Pregelatinized Corn	Starch, Pregelatinized Tapioca
Stearalkonium Chloride	Stearyl Citrate	Stearyl Monoglyceridyl Citrate
Succinylated Monoglycerides	Sucrose Acetate Isobutyrate	Sucrose Fatty Acid Esters
Sucrose Stearate	Sucrose Syrup	Sugar Fruit Fine
Sulfobutyl Ether Beta Cyclodextran	Tallow	Tallow Glycerides
Tallow Oil	Tetrafluoroethane	Thioglycerol
Thyme Oil	Tribehenin	Triceteareth-4 Phosphate
Trichloroethylene	Trimyristin	Trisidium Citrate
Trolamine Lauryl Sulfate	Vegetable Oil	Wheat Flour
Wheat Gluten	Wheat Germ Oil	Whey

**PHARMACOPEIAL EDUCATION COURSES.** USP's Pharmacopeial Education courses offer specialized instruction for chemists, other scientists, and professionals in the pharmaceutical and allied industries. USP scientists who play a key role in establishing official USP standards teach these courses and provide expert insights on the practical applications of official test procedures and best practices in using the *USP–NF* and other USP resources. The courses also give participants an opportunity to learn

how to get involved in USP's standards-setting processes and the benefits of participating in standards development. Courses offered in 2005 and 2006 are listed below. For more information and to register, visit [www.usp.org](http://www.usp.org). To discuss how USP can bring courses to a location of your choice or design a custom course package for you, call 301-816-8237, or e-mail [PharmacoepialEducation@usp.org](mailto:PharmacoepialEducation@usp.org).

**2005–2006 Calendar of Pharmacopeial Education Courses**

Date	Name of Course	Location
November 4	Fundamentals of Microbiological Testing	California State University, Fullerton, CA
November 15	Basic Statistics and Their Practical Applications to the <i>USP–NF</i>	North Carolina State University, Raleigh, NC
December 7	Effectively Using the <i>USP–NF</i> : Session I	Brussels, Belgium
December 8	Effectively Using the <i>USP–NF</i> : Session II	Brussels, Belgium
January 18	Effectively Using the <i>USP–NF</i> : Sessions I & II	California State University, Fullerton, CA
January 24–25	Fundamentals of Dissolution: Lecture & Lab	North Brunswick, NJ
February 14	Effectively Using the <i>USP–NF</i> : Sessions I & II	Basel, Switzerland
February 15	Analytical Method Validation	Basel, Switzerland
February 23	Effectively Using the <i>USP–NF</i> : Sessions I & II	North Carolina State University, Raleigh, NC
March 29	Basic Statistics and Their Practical Applications to the <i>USP–NF</i>	New Jersey, hosted by NJQCA
April 19	Effectively Using the <i>USP–NF</i> : Session I	USP Headquarters, Rockville, MD
April 20	Effectively Using the <i>USP–NF</i> : Session II	USP Headquarters, Rockville, MD

**VISIT THE USP WEB SITE AT** (<http://www.usp.org>). Various resources related to Pharmacopeial standards are presented, including highlights from *PF*.

**INTERNATIONAL CORRESPONDENCE.** Individuals who wish to correspond with the European and Japanese Pharmacopoeias concerning monographs in the Official Inquiry and Consensus stages of international harmonization should address their comments to the coordinating pharmacopeia, with a copy to USP, for a given article. The addresses for the European and Japanese Pharmacopoeias are as follows:

Technical Secretariat of the European  
Pharmacopoeia Commission  
B.P. 907  
F 67029 Strasbourg Cedex 1  
France

NAKASHIMA Nobumasa  
Evaluation and Licensing Division  
Pharmaceutical and Medical Safety Bureau  
Ministry of Health, Labour and Welfare, Japan  
Tel. +81-3-3595-2431, Fax +81-3-3597-9535  
E-mail: [nakashima-nobumasa@mhlw.go.jp](mailto:nakashima-nobumasa@mhlw.go.jp)

**HOW TO SUBMIT COMMENTS.** The USP welcomes and encourages interested parties to submit comments and data regarding potential, proposed, or adopted (official) standards. Submissions concerning a particular item that has appeared in an issue of *PF* should be submitted to the appropriate USP scientific staff liaison identified at the end of the *Briefing* accompanying each item. To submit comments and data to a liaison, use the e-mail address and telephone numbers listed in the *Staff Directory* included in every *PF*.

Please note that *USP–NF* is being published in an annual edition with one main book and two *Supplements* a year. In addition, the schedule provided below will repeat every year so that users will know what to expect and become familiar with the deadlines.

In the future, USP anticipates including the comment submission deadline in each briefing of every revision proposal when it is published for public review and comment.

For general inquiries or in cases where a particular liaison is not identified, use the general USP telephone number 301-881-0666 or FAX number 301-816-8373.

**NEW PHARMACOPEIAL FORUM PUBLIC REVIEW AND COMMENT PERIOD DEADLINES.** In *Pharmacopeial Forum* 31(5) (page 1308), USP announced that the comment period for *PF* proposals targeted for the *USP–NF* and its *Supplements* has been extended to a period of 90 days from the date of publication, as opposed to the 60-day period previously provided.

The comment deadlines for *PF* 31(6) and beyond were inadvertently omitted from the *Policies and Announcements* section of *PF* 31(6). The full year’s listing of comment period deadlines and the targeted official publications appear

below. In accordance with the Rules and Procedures of the 2005–2010 Council of Experts\*, USP is implementing the 90-day comment period by providing a deadline for each issue of *PF* unless otherwise stated in the individual briefing. Note that *PF* 31(6) and *PF* 32(1) have a combined comment deadline (April 17, 2006) due to the omission of the comment deadline dates in *PF* 31(6). Individual comment deadlines begin with *PF* 32(2) March–April 2006.

We apologize for any inconvenience this may have caused.

**Publication and Comment Schedule**

Pharmacopeial Forum	Comment Deadline	Targeted Official Publication	Publication Date	Official Date
<i>PF</i> 31(6)	April 17, 2006	<i>USP 30–NF 25</i>	November 2006	January 2007
<i>PF</i> 32(1)	April 17, 2006			
<i>PF</i> 32(2)	June 15, 2006	<i>USP 30–NF 25 1st Supplement</i>	February 2007	April 2007
<i>PF</i> 32(3)	August 15, 2006			
<i>PF</i> 32(4)	October 16, 2006			
<i>PF</i> 32(5)	December 15, 2006	<i>USP 30–NF 25 2nd Supplement</i>	June 2007	August 2007
<i>PF</i> 32(6)	February 15, 2007			
<i>PF</i> 33(1)	April 16, 2007	<i>USP 31–NF 26</i>	November 2007	January 2008

All official revisions are published in the annual edition or *Supplements* to *USP–NF* (twice yearly). Between these publications, official revisions are published in *PF* in the *Interim Revision Announcement*; these revisions are also incorporated in the upcoming *Supplement*. The official publication in which an *IRA* is incorporated will depend upon publication deadlines. The 5th *IRA* and the 6th *IRA* will not appear until *Supplement 1*. See table below. The electronic version of *USP–NF* is updated as each *Supplement* becomes available and, therefore, contains all official text up to and including the contents of the latest *Supplement*. The new table below outlines the publications and their release and official dates, and the book or supplement which supersedes them.

\* **Section 9.04(b) of the Rules and Procedures of the 2005–2010 Council of Experts**

*A period of at least ninety (90) days from the date of publication will be allowed for public review and comment. The time allowed for public comments shall be noted in the publication in the PF. For good cause shown, the Chairperson may alter the time specified.*

## Publication Schedules

Publication	Release Date	Official Date	Superseded by
<i>USP 29–NF 24</i>	Nov. 1, 2005	Jan. 1, 2006	<i>1st Supplement</i>
<i>1st Supplement</i>	Feb. 1, 2006*	Apr. 1, 2006*	<i>2nd Supplement</i>
1st <i>IRA</i> [PF 32(1)]	Jan. 1, 2006*	Feb. 1, 2006*	<i>2nd Supplement</i>
2nd <i>IRA</i> [PF 32(2)]	Mar. 1, 2006*	Apr. 1, 2006*	<i>2nd Supplement</i>
3rd <i>IRA</i> [PF 32(3)]	May 1, 2006*	June 1, 2006*	<i>USP 30–NF 25</i>
<i>2nd Supplement</i>	June 1, 2006*	Aug. 1, 2006*	<i>USP 30–NF 25</i>
4th <i>IRA</i> [PF 32(4)]	July 1, 2006*	Aug. 1, 2006*	<i>USP 30–NF 25</i>
5th <i>IRA</i> [PF 32(5)]	Sept. 1, 2006*	Oct. 1, 2006*	<i>1st Supplement USP 30–NF 25</i>
6th <i>IRA</i> [PF 32(6)]	Nov. 1, 2006*	Dec. 1, 2006*	<i>1st Supplement USP 30–NF 25</i>
<i>USP 30–NF 25</i>	Nov. 1, 2006*	Jan. 1, 2007*	

\*Tentative

## Instructions to Authors

Contributions in the form of original research reports, evaluations of new and existing compendial methods, and other commentaries and articles relevant to drug standards or to *USP–NF* revision will be considered for publication in the *Pharmacopeial Forum* under the section *Stimuli to the Revision Process*. Manuscripts are received with the explicit understanding that they have not been published previously and that they are not simultaneously under consideration by any other publication.

All manuscripts are subject to review by USP headquarters staff, Committee members, or qualified outside referees, and if accepted for publication will be subject to editing by USP staff. Accepted manuscripts become the property of the USP Convention (USPC) and may not be published elsewhere without written permission from the USPC. Authors are also responsible for obtaining permission for reprinting any illustrations that have been published elsewhere.

**Abstract**—Include an abstract of not more than 250 words stating the purpose and the results or conclusions of the article.

**References**—Consult a current copy of the *Pharmacopeial Forum* and the *ACS Style Guide* for assistance with reference style.

**Copyright**—Copyright transfer documents will be sent to authors after manuscripts have been accepted for publication.

**Contact Person**—When submitting a manuscript, designate one author of the article as correspondent and include that author's full address, telephone number, fax number, and e-mail address.

**Submission Instructions**—Manuscripts must be submitted both as an electronic file and as a printed copy of the electronic file. Submit the text in Microsoft® Word or another current word-processing application. The preferred format for graphics submitted electronically is tagged image file format (TIFF). Graphics that cannot be submitted electronically must be camera-ready, of easily reproducible quality and size, and clearly labeled. Photocopies are not acceptable. Manuscripts submitted for publication should be addressed to:

Pharmacopeial Forum  
Executive Secretariat, USP  
12601 Twinbrook Pkwy.  
Rockville, MD 20852


## USP Dictionary of USAN and International Drug Names 2005 USP DICTIONARY SUPPLEMENT 5

**IMPORTANT**—Save this Supplement. This and all supplements appearing in *PF* are needed to keep the 2005 edition of the USP Dictionary (USPD) up-to-date. The cumulative contents of the supplements to the current (2005) edition will be included in the next complete edition of the Dictionary.


### Newly Approved United States Adopted Names (USAN), Released for Publication

The following are newly established United States Adopted Names (USAN). These names will not be listed cumulatively; see preceding and succeeding numbers of *PF* for other new USAN to supplement the Dictionary main volume.


**Apadenoson** [2005] (a pa den' oh son). C<sub>23</sub>H<sub>30</sub>N<sub>6</sub>O<sub>6</sub>. 486.50. (1) Cyclohexanecarboxylic acid, 4-[3-[6-amino-9-(*N*-ethyl-β-D-ribofuranuronamidoyl)-9*H*-purin-2-yl]-2-propynyl]-, methyl ester, *trans*-; (2) Methyl *trans*-4-[3-[6-amino-9-(*N*-ethyl-β-D-ribofuranosyluronamide)-9*H*-purin-2-yl]prop-2-ynyl]cyclohexanecarboxylate. *CAS*-250386-15-3. *Adjunct to nuclear myocardial perfusion imaging in patients unable to exercise adequately.* (Bristol-Myers Squibb) ◇*BMS068645*




**Darapladib** [2005] (dar ap' la lib). C<sub>36</sub>H<sub>38</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>S. 666.80. (1) 1*H*-Cyclopentapyrimidine-1-acetamide, *N*-[2-(diethylamino)ethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-*N*-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-; (2) *N*-[2-(Diethylamino)ethyl]-2-[2-[(4-fluorobenzyl)sulfanyl]-4-oxo-4,5,6,7-tetrahydro-1*H*-cyclopentapyrimidin-1-yl]-*N*-[[4'-(trifluoromethyl)biphenyl-4-yl]methyl]acetamide. *CAS*-356057-34-6. *Treatment of atherosclerosis.* (GlaxoSmithKline) ◇*SB-480848*




**Cangrelor** [2005] (kan' grel or). C<sub>17</sub>H<sub>25</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>5</sub>O<sub>12</sub>P<sub>3</sub>S<sub>2</sub>. 776.36. (1) 5'-Adenylic acid, *N*-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-, monoanhydride with (dichloromethylene)bis[phosphonic acid]; (2) (Dichloromethylene)diphosphonic *N*-[2-(methylsulfanyl)ethyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]-5'-adenylic monoanhydride. *CAS*-163706-06-7. *INN*; *BAN*. *Anti-platelet agent.* (Medical Arts) ◇*AR-C69931XX*




**Cangrelor Tetrasodium** [2005] (kan' grel or). C<sub>17</sub>H<sub>21</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>5</sub>Na<sub>4</sub>O<sub>12</sub>P<sub>3</sub>S<sub>2</sub>. 864.30. (1) 5'-Adenylic acid, *N*-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-, monoanhydride with (dichloromethylene)bis[phosphonic acid], tetrasodium salt; (2) *N*-[2-(Methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid, monoanhydride with (dichloromethylene)diphosphonic acid tetrasodium salt. *CAS*-163706-36-3. *Antiplatelet agent.* (Medical Arts) ◇*AR-C69931MX*




**Dimethyl Fumarate** [2005] (dye meth' il fue' ma rate). C<sub>6</sub>H<sub>8</sub>O<sub>4</sub>. 144.10. (1) 2-Butenedioic acid, (2*E*)-, dimethyl ester; (2) Dimethyl (2*E*)-but-2-enedioate. *CAS*-624-49-7. *Immunomodulator.* (Biogen Idec) ◇*AZL O 211089*




**Eltrombopag Olamine** [2005] (el trom' boe pag). C<sub>25</sub>H<sub>22</sub>N<sub>4</sub>O<sub>4</sub> · 2(C<sub>2</sub>H<sub>7</sub>NO). 564.60. (1) [1,1'-Biphenyl]-3-carboxylic acid, 3'-[(2*Z*)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4*H*-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-, compound with 2-aminoethanol (1:2); (2) 3'-[(2*Z*)-2-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4*H*-pyrazol-4-ylidene]diazanyl]-2'-hydroxybiphenyl-3-carboxylic acid compound with 2-aminoethanol (1:2). *CAS*-496775-62-3. *Treatment of chemotherapy-induced thrombocytopenia and treatment of immune thrombocytopenic purpura.* (GlaxoSmithKline) ◇*SB-497115-GR*



**Fospropofol Disodium** [2005] (fos proe poe' fol).  $C_{13}H_{19}Na_2O_5P$ . 332.20. (1) Methanol, [2,6-bis(1-methylethyl)phenoxy]-, dihydrogen phosphate, disodium salt; (2) [2,6-Bis(1-methylethyl)phenoxy]methyl disodium phosphate; (3) 2,6-Diisopropylphenoxyethyl phosphate, disodium salt. *CAS-258516-87-9. Procedural sedation.* Aquavan (Guilford)




**Goxalapladi** [2005] (gox a lap' la dib).  $C_{40}H_{39}F_5N_4O_3$ . 718.80. (1) 1,8-Naphthyridine-1(4*H*)-acetamide, 2-[2-(2,3-difluorophenyl)ethyl]-*N*-[1-(2-methoxyethyl)-4-piperidinyl]-4-oxo-*N*-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-; (2) 2-[2-[2-(2,3-Difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-*N*-[1-(2-methoxyethyl)piperidin-4-yl]-*N*-[[4'-(trifluoromethyl)biphenyl-4-yl]methyl]acetamide; (3) 2-[2-(2,3-Difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-*N*-[1-(2-methoxyethyl)piperidin-4-yl]-*N*-[[4'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl]acetamide. *CAS-412950-27-7. Treatment of atherosclerosis.* (GlaxoSmithKline)




**Inalimarev (CEA, MUC-1, Vaccinia virus)** [2005] (in a lim' a rev). PANVAC-V. The genome size is approximately 290,000 ± 50,000. *CAS-685563-13-7. Treatment of pancreatic cancer, CEA-bearing tumors.* Panvac (Therion Biologics)

**Incyclinide** [2005] (in sye' kli nide).  $C_{19}H_{17}NO_7$ . 371.30. (1) 2-Naphthacenicarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4a*S*,5a*R*,12a*S*)-; (2) (4a*S*,5a*R*,12a*S*)-3,10,12,12a-Tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrodrotetracene-2-carboxamide. *CAS-15866-90-7. Treatment of acne, rosacea, and acute respiratory distress syndrome.* Metastat (CollaGenex) ◇*COL-3*




**Iratumumab** [2005] (ir' a toom' ue mab). Immunoglobulin G1, anti-(human CD30 (antigen)) (human monoclonal MDX-060 heavy chain), disulfide with human monoclonal MDX-060 light chain, dimer. Molecular weight is approximately 170,000 daltons. *CAS-640735-09-7. Oncological diseases; treatment of relapsed or refractory CD30 positive lymphoma including Hodgkin's Disease.* (Medarex) ◇*MDX-060*


**Lisdexamfetamine Dimesylate** [2005] (lis dex'' am fet' a meen).  $C_{15}H_{25}N_3O \cdot (CH_4O_3S)_2$ . 455.60. (1) Hexanamide, 2,6-diamino-*N*-[(1*S*)-1-methyl-2-phenylethyl]-, (2*S*)-, dimethanesulfonate; (2) (2*S*)-2,6-Diamino-*N*-[(1*S*)-1-methyl-2-phenylethyl]hexanamide dimethanesulfonate. *CAS-608137-33-3. Treatment of attention deficit hyperactivity disorder (ADHD).* (New River) ◇*NRP104*




**Migalastat Hydrochloride** [2005] (mi gal' a stat).  $C_6H_{13}NO_4 \cdot HCl$ . 199.63. (1) 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, hydrochloride, (2*R*,3*S*,4*R*,5*S*)-; (2) (+)-(2*R*,3*S*,4*R*,5*S*)-2-(Hydroxymethyl)piperidine-3,4,5-triol hydrochloride; (3) 1,5-Dideoxy-1,5-imino-D-galactitol hydrochloride. *CAS-75172-81-5. Treatment of Fabry disease.* (Amicus Therapeutics)




**Pazopanib Hydrochloride** [2005] (paz oh' pa nib).  $C_{21}H_{23}N_7O_2S \cdot HCl$ . 474.00. (1) Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2*H*-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-, monohydrochloride; (2) 5-[[4-[(2,3-Dimethyl-2*H*-indazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide monohydrochloride. *CAS-635702-64-6. Antineoplastic agent, a potent and selective inhibitor of VEGFR-1, -2, and -3 tyrosine kinases, blocking angiogenesis.* (GlaxoSmithKline) ◇*GW786034B*




**Rilapladi** [2005] (ri lap' la dib).  $C_{40}H_{39}F_5N_3O_3S$ . 735.80. (1) 1(4*H*)-Quinolineacetamide, 2-[[[(2,3-difluorophenyl)methyl]thio]-*N*-[1-(2-methoxyethyl)-4-piperidinyl]-4-oxo-*N*-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-; (2) 2-[2-[[2-(2,3-Difluorobenzyl)sulfanyl]-4-oxoquinolin-1(4*H*)-yl]-*N*-[1-(2-methoxyethyl)piperidin-4-yl]-*N*-[[4'-(trifluoromethyl)-biphenyl-4-yl]methyl]acetamide. *CAS-412950-08-4. Treatment of atherosclerosis.* (GlaxoSmithKline) ◇*SB-659032*




**Rotigaptide** [2005] (roe ti gap' tide).  $C_{28}H_{39}N_7O_9$ . 617.70. (1) Glycinamide, *N*-acetyl-D-tyrosyl-D-prolyl-(4*S*)-4-hydroxy-D-prolylglycyl-D-alanyl-; (2) *N*-Acetyl-D-tyrosyl-D-prolyl-(4*S*)-4-hydroxy-D-prolylglycyl-D-alanylglycinamide. *CAS*-355151-12-1. *Treatment of ventricular tachycardia or ventricular fibrillation.* (Wyeth/Zeland)  $\diamond$ GAP (Wyeth); ZP-123 (Zeland)



**Sapropterin Dihydrochloride** [2005] (sap'' roe ter' in).  $C_9H_{15}N_5O_3 \cdot 2HCl$ . 314.20. [Sapropterin is INN.] (1) 4(1*H*)-Pteridinone, 2-amino-6-[(1*R*,2*S*)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-, dihydrochloride, (6*R*)-; (2) (6*R*)-2-Amino-6-[(1*R*,2*S*)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-4(1*H*)-pteridinone dihydrochloride. *CAS*-69056-38-8; *CAS*-62989-33-7 [sapropterin]. *Treatment of mild-to-moderate phenylketonuria (PKU).* (BioMarin)  $\diamond$ T1401 (BioMarin); SUN-0588 (Shiratori)




**Sarizotan Hydrochloride** [2005] (sar i zoe' tan).  $C_{22}H_{21}FN_2O \cdot HCl$ . 384.90. [Sarizotan is INN.] (1) 3-Pyridinemethanamine, *N*-[[[(2*R*)-3,4-dihydro-2*H*-1-benzopyran-2-yl]methyl]-5-(4-fluorophenyl)-, monohydrochloride; (2) (-)-*N*-[[[(2*R*)-3,4-dihydro-2*H*-1-benzopyran-2-yl]methyl]-5-(4-fluorophenyl)pyridine-3-yl]methanamine monohydrochloride. *CAS*-195068-07-6; *CAS*-177975-08-5 [sarizotan]. *Treatment-associated dyskinesia in Parkinson's disease.* (EMD)  $\diamond$ EMD 128130




**Stamulumab** [2005] (sta mul' ue mab). Immunoglobulin G1, anti-(human growth differentiation factor 8) (human MYO-029 heavy chain), disulfide with human MYO-029  $\lambda$ -chain, dimer. *CAS*-705287-60-1. *Treatment of muscular dystrophy and age-related sarcopenia or frailty.* (Wyeth)  $\diamond$ MYO-029

**Tolevamer Potassium Sodium** [2005] (tol ev' am er).  $(C_8H_7O_3S)_n \cdot K_{(n-a)} \cdot Na_a$ . (1) Benzenesulfonic acid, 4-ethenyl-, potassium salt, polymer with sodium 4-ethenylbenzenesulfonate; (2) Poly[1-(4-sulfophenyl)ethylene], potassium sodium salt. Molecular weight is greater than 400,000 daltons. *CAS*-81998-90-5. *Treatment of Clostridium difficile associated diarrhea.* (Genzyme)  $\diamond$ GT267-004



**Vicriviroc Maleate** [2005] (vi'' kri vir' ok).  $C_{28}H_{38}F_3N_5O_2 \cdot C_4H_4O_4$ . 649.70. (1) Piperidine, 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[(3*S*)-4-[(1*R*)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-, (2*Z*)-2-butenedioate (1:1); (2) 1-[(4,6-Dimethylpyrimidin-5-yl)carbonyl]-4-[(3*S*)-4-[(1*R*)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidine (2*Z*)-but-2-enedioate. *CAS*-599179-03-0. *Antiviral, CCR5 antagonist, treatment of autoimmune conditions.* (Schering-Plough Research)  $\diamond$ SCH 417690



## Proposed and Recommended International Nonproprietary Names

International Nonproprietary Names (INN) are devised by the World Health Organization (WHO).

Under its charter, the WHO is empowered simply to *recommend* specific actions or procedures to its Member States. This limitation is incorporated into the WHO program concerned with the selection of international nonproprietary names for pharmaceutical substances, in that the WHO first publishes the selected names as *proposals* (“Proposed International Nonproprietary Names”). A period of four months from the date of publication in *WHO Drug Information* is allowed for entering comments on, or objections to,

any proposal on the part of Member States or other interested parties. In general, an objection reflects a belief that the proposal concerned is confusingly close to (i.e., conflicts with) a name already in use, perhaps in only a restricted area in which the party has a proprietary interest in the form of trademark rights. In the event that no objection is received, the WHO proceeds with listing and publishing the names so devised as *recommendations* (“Recommended International Nonproprietary Names”), which many Member States then recognize as the sole or preferred nonproprietary name for use within their respective territories.

## Recommended International Nonproprietary Names

The following 58 nonproprietary names have been selected by the World Health Organization (WHO) as Recommended International Nonproprietary Names. This list, with chemical names or

descriptions and the molecular formulae, appears in *WHO Drug Information*, Vol. 19, No. 3, 2005.

Recommended INN	Recommended INN	Recommended INN	Recommended INN
Ancriviroc	Deferitrin	Inotuzumab Ozogamicin	Raxibacumab
Aplindore	Delmitide	Isalmadol	Rimeporide
Atilmotin	Deutolperisone	Ispinesib	Salclobuzic Acid
Avanafil	Efipladib	Levotofisopam	Saxagliptin
Balicatib	Elomotecan	Linaprazan	Seliciclib
Becatecarin	Embeconazole	Morphine Glucuronide	Sugammadex
Becocalcidiol	Epoetin Zeta	Naveglitazar	Talabostat
Bemotrizinol	Eritoran	Omocianine	Talactoferrin Alfa
Besilesomab	Etalocib	Peliglitazar	Talaglumetad
Bisotrizole	Farampator	Pemaglitazar	Tanogitran
Canfosfamide	Forodesine	Perflisobutane	Tefibazumab
Ceftobiprole	Galsulfase	Piclozotan	Temsirolimus
Ceftobiprole Medocaril	Glucarpidase	Pralatrexate	Tetomilast
Cintredekin Besudotox	Ibocadekin	Radotermin	Thrombomodulin Alfa
Davasaicin	Icomucret		